Generic Name and Formulations:
Quinapril (as HCl), hydrochlorothiazide; 10mg/12.5mg (+), 20mg/12.5mg (+), 20mg/25mg; tabs; scored (+).
Company:
Pfizer Inc.
Hypertension.
Not for initial therapy. Previously titrated: use same doses as individual components. Switching from quinapril monotherapy: initially one Accuretic 10/12.5 tab or one Accuretic 20/12.5 tab once daily; allow 2–3 weeks before increasing hydrochlorothiazide component. Switching from hydrochlorothiazide 25mg/day monotherapy: initially one Accuretic 10/12.5 tab daily or one Accuretic 20/12.5 tab once daily. Adjust based on response and serum potassium. Renal impairment (CrCl ≤30mL/min): not recommended.
Not established.
ACE inhibitor + diuretic.
Anuria. Sulfonamide allergy. History of ACEI-associated or other angioedema. Concomitant aliskiren in diabetes patients.
Fetal toxicity may develop; discontinue if pregnancy is detected. Salt/volume depletion. Renal or hepatic impairment. Ischemic heart disease. Diabetes. Dialysis (esp. high-flux membrane). Postsympathectomy. Surgery. SLE. Acute myopia and secondary angle-closure glaucoma. History of angioedema. Severe CHF. Cerebrovascular disease. Gout. Black patients may have a higher risk of angioedema than non-blacks. Monitor: electrolytes, renal function in severe CHF and renal artery stenosis, WBCs in collagen vascular disease and/or renal disease. Discontinue if angioedema, laryngeal edema, jaundice or marked elevation in liver enzymes occurs. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
See Contraindications. Orthostatic hypotension potentiated by alcohol, CNS depressants. Hyperkalemia with K+ supplements, K+ containing salt substitutes, K+ sparing diuretics. Hypokalemia more likely with corticosteroids, ACTH. Reduces tetracycline absorption (Accuretic contains magnesium). May increase lithium levels. Antagonized by NSAIDs, cholestyramine, colestipol resins. Potentiates nondepolarizing muscle relaxants. Monitor antidiabetic agents. May interfere with parathyroid tests. May antagonize pressor amines. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended.
Cough, headache, somnolence, orthostatic hypotension, electrolyte disturbances; rare: angioedema, anaphylactoid reactions, excessive hypotension, hepatic failure, neutropenia, agranulocytosis.
Quinapril: hepatic
Renal.
YES
Tabs—90